HSR paperwork whiplash is not a meme, but it is a real uncertainty tax - and healthcare deals wear it
The Opportunity
The signal is a procedural shift in US antitrust plumbing: after a court vacated the expanded HSR regime, the FTC premerger office reverted to accepting the pre-2025 forms. The market impact is not in any single case outcome; it is in the uncertainty premium around deal timelines and disclosure expectations, which shows up disproportionately in healthcare and pharma distribution where M&A optionality is a real part of the valuation story. That uncertainty premium argues for a SHORT on the sector proxies (IHE/XBI) in the near term, even if the procedural change sounds like relief on paper.
The Timing
Freshness is 85 and validation is partially confirmed, but the macro regime is Mixed 28 with low wind strength, so this is about idiosyncratic headline risk rather than tape. The key missing confirmation that would strengthen the trade is evidence that the FTC/DOJ is compensating for the form rollback by extracting the same information via second requests at scale; the key contradictor is a quiet period where the rollback actually reduces friction without any compensating enforcement intensity. Until then, treat this as an uncertainty-volatility short, not a clean structural bet.
The Evidence
The primary artefact in this payload is the practitioner summary at deallawyers.com , which cites FTC PNO notices in March 2026 and lays out what filers are being told to do. The broader practitioner echo (law firm memos) reinforces that this is an operational change, not a rumour; one example surfaced in due diligence is Orrick's memo at orrick.com . The absence of retail chatter is the point: this is the kind of detail that moves behaviour before it moves headlines.